Clinical Trials Logo

Refractory Ascites clinical trials

View clinical trials related to Refractory Ascites.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06196723 Completed - Refractory Ascites Clinical Trials

Early Transjugular Intrahepatic Portosystemic Shunts Improve Survival in Patients With Cirrhosis and Recurrent Ascites

TIPS
Start date: December 1, 2023
Phase:
Study type: Observational

Currently, there is limited evidence regarding the survival benefit of early transjugular intrahepatic portal shunt (TIPS) placement in patients with cirrhosis and recurrent ascites. This observational study aimed to assess whether early TIPS improves the survival of patients with advanced cirrhosis and recurrent ascites. We will compare large volume paracenteses plus albumin (LVP+A) to see if TIPS improves the survival of patients with advanced cirrhosis and recurrent ascites.

NCT ID: NCT01532427 Completed - Liver Cirrhosis Clinical Trials

ALFApump System Post Marketing Surveillance Registry

2011-AAR-004
Start date: June 2012
Phase:
Study type: Observational [Patient Registry]

This is a post market surveillance registry to monitor the safety and performance of the ALFApump system.

NCT ID: NCT01440829 Completed - Portal Hypertension Clinical Trials

The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS

Start date: December 2011
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this study is to evaluate the effectiveness of L-ornithine-L-aspartate (LOLA) on plasma ammonia in cirrhotic patients after Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure.

NCT ID: NCT00870662 Completed - Refractory Ascites Clinical Trials

A Feasibility Study of the Automated Fluid Shunt (AFS) for Automated Ascites Removal

Start date: December 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the Automatic Fluid Shunt (AFS) can reduce the number of paracentesis procedures in patients with refractory ascites.

NCT ID: NCT00240045 Completed - Refractory Ascites Clinical Trials

The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction

Start date: October 2005
Phase: Phase 2/Phase 3
Study type: Interventional

We will address the hypothesis that refractory ascites and Type 2 hepatorenal syndrome are mediated in part by diminished circulatory volume and that treatment with midodrine, octreotide and albumin can improve renal and patient outcomes by restoring effective circulating volume and systemic perfusion. Our primary objective is to assess change in creatinine clearance using inulin. We will enroll 15 patients with Type 2 hepatorenal syndrome or refractory ascites once inclusion and exclusion criteria are satisfied. They will be treated for 1 month with octreotide LAR, albumin and midodrine. Renal, serum and neurohormonal parameters will be measured before, during, and after initiation of drug and compared.